Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (10)

2024

  1. KDM6A regulates immune response genes in multiple myeloma

    Blood

  2. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2022

  1. The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells

    Leukemia, Vol. 36, Núm. 8, pp. 1969-1979

2021

  1. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    Leukemia, Vol. 35, Núm. 12, pp. 3542-3550

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566

  2. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma

    Cell Reports, Vol. 19, Núm. 1, pp. 218-224

2016

  1. Targeting vasculogenesis to prevent progression in multiple myeloma

    Leukemia, Vol. 30, Núm. 5, pp. 1103-1115

2015

  1. Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape

    Cell Reports, Vol. 12, Núm. 8, pp. 1300-1313

2013

  1. EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

    Cancer Cell, Vol. 23, Núm. 5, pp. 677-692

2010

  1. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma

    Clinical Cancer Research, Vol. 16, Núm. 12, pp. 3260-3269